title: Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee.
authors.affiliation: Office of Pharmaceutical Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Williams
authors.forename: W
authors.initials: W
authors.lastname: Adams
authors.forename: M L
authors.initials: ML
authors.lastname: Chen
authors.forename: D
authors.initials: D
authors.lastname: Hare
authors.forename: A
authors.initials: A
authors.lastname: Hussain
authors.forename: L
authors.initials: L
authors.lastname: Lesko
authors.forename: R
authors.initials: R
authors.lastname: Patnaik
authors.forename: V
authors.initials: V
authors.lastname: Shah
mesh_terms: D001682:Biological Availability; D004282:Documentation / Q000379:methods / Q000592:standards; D004345:Drug Industry; D005544:Forecasting; D006801:Humans; D010599:Pharmacokinetics; D013810:Therapeutic Equivalency